Academician Xu Zhang: Advancing Surgery and Systemic Therapy in Parallel—China’s Comprehensive Management of Urologic Cancers Moves to the Global Forefront

Academician Xu Zhang: Advancing Surgery and Systemic Therapy in Parallel—China’s Comprehensive Management of Urologic Cancers Moves to the Global Forefront

2026.01.12
The 9th West China Urologic Oncology Tianfu Academic Conference and the 11th Annual Academic Meeting on Urologic and Male Genitourinary Tumors of the Sichuan Anti-Cancer Association were recently held successfully in Chengdu, Sichuan. Centered on urologic and male genitourinary malignancies, the conference emphasized timeliness and diversity, combining a global perspective with Chinese clinical realities to build a high-level platform for academic exchange and innovation in urologic oncology. During the meeting, Oncology Frontier – Urology Frontier invited Academician Xu Zhang from The Third Medical Center, Chinese PLA General Hospital to share his insights on China’s distinctive achievements in minimally invasive surgery, recent advances in systemic therapy, and their clinical value.
Professor Ng Chi Fai: New Advances in Adjuvant Therapy for Renal Cell Carcinoma and Optimization of Clinical Decision-Making | 15th Shanghai Academic Conference on Urologic Oncology

Professor Ng Chi Fai: New Advances in Adjuvant Therapy for Renal Cell Carcinoma and Optimization of Clinical Decision-Making | 15th Shanghai Academic Conference on Urologic Oncology

2026.01.12
For many years, adjuvant therapy for renal cell carcinoma (RCC) remained in a state of “therapeutic vacuum.” RCC is intrinsically resistant to radiotherapy and chemotherapy, and early attempts to introduce targeted therapies into the adjuvant setting failed to deliver meaningful benefits. The success of the KEYNOTE-564 trial has been a turning point—ushering RCC adjuvant therapy into the era of immunotherapy and redefining postoperative management for high-risk patients.
Voice of China at ASH | Professor Wang Huafeng: Reconstructing Survival Prediction in Acute Myeloid Leukemia Through Multi-Omics Decoupling and Fusion

Voice of China at ASH | Professor Wang Huafeng: Reconstructing Survival Prediction in Acute Myeloid Leukemia Through Multi-Omics Decoupling and Fusion

2026.01.11
The 67th Annual Meeting of the American Society of Hematology (ASH) was held in Orlando, USA, from December 6 to 9, 2025, bringing together the latest research advances and clinical progress in hematology worldwide. At this year’s meeting, Professor Wang Huafeng’s team from The First Affiliated Hospital, Zhejiang University School of Medicine had six studies accepted, including one oral presentation and five poster presentations, with one poster receiving the ASH Outstanding Abstract Award. These achievements highlight the growing international academic influence of Chinese researchers in the field of acute leukemia.
Breakthroughs by Chinese Investigators in the Treatment of Metastatic Urothelial Carcinoma

Breakthroughs by Chinese Investigators in the Treatment of Metastatic Urothelial Carcinoma

2026.01.10
At a recent academic conference on urologic oncology, Professor Jun Guo from Peking University Cancer Hospital & Institute delivered an important presentation systematically reviewing the ten-year journey of Chinese researchers in the field of drug therapy for urothelial carcinoma (UC)—from following international trends to taking a leading role. His lecture focused on the landmark achievements of China-originated antibody–drug conjugates (ADCs), represented by disitamab vedotin (RC48), particularly when combined with immunotherapy. Based on Professor Guo’s presentation, this article aims to showcase the international leap achieved by Chinese research in urologic oncology.
Professor Jingjing Wang Provides an In-Depth Analysis of Precision Strategies and PARP Inhibitor–Based Combinations in Prostate Cancer

Professor Jingjing Wang Provides an In-Depth Analysis of Precision Strategies and PARP Inhibitor–Based Combinations in Prostate Cancer

2026.01.10
In 2025, the 15th Shanghai Urologic Oncology Academic Conference was grandly held in Pudong, Shanghai. The meeting convened leading experts in urologic oncology from across China to discuss cutting-edge diagnostic and therapeutic strategies for genitourinary malignancies, including prostate cancer, renal cell carcinoma, and bladder cancer. During the conference, Professor Jingjing Wang, representing the field of medical oncology, delivered an outstanding presentation grounded in the latest evidence-based data, focusing on precision treatment strategies for metastatic castration-resistant prostate cancer (mCRPC), with particular emphasis on combination regimens involving PARP inhibitors. Based on Professor Wang’s presentation, this article systematically reviews the therapeutic challenges of mCRPC, genetic screening strategies, and the clinical benefits of emerging combination approaches, with the aim of providing practical insights for clinicians.
Professor Xiaolin Lu Offers an In-Depth Analysis of the BCG Dilemma and the Future of Novel Intravesical and Combination Immunotherapies

Professor Xiaolin Lu Offers an In-Depth Analysis of the BCG Dilemma and the Future of Novel Intravesical and Combination Immunotherapies

2026.01.10
Editor’s Note: The 15th Shanghai Urologic Oncology Academic Conference was grandly held in Pudong, Shanghai, bringing together leading experts in urologic oncology from China and abroad. The meeting focused on bladder-sparing strategies for non–muscle-invasive bladder cancer (NMIBC), advances in novel intravesical agents, and the latest developments in immunotherapy. At the conference, Professor Xiaolin Lu from Fudan University Shanghai Cancer Center delivered a dedicated presentation from the perspective of intravesical therapy, systematically outlining the challenges in NMIBC management. He highlighted groundbreaking clinical trial results from the Fudan Cancer Center team on novel intravesical agents—particularly interleukin-15 (IL-15) and its fusion proteins, modified chemotherapeutic formulations, and oncolytic viruses—painting a new blueprint for the future treatment of NMIBC.